Zepbound Doses: All Six Strengths, the FDA Titration Schedule, and What Each One Does

Key Takeaways

• Zepbound is available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each delivered weekly via subcutaneous injection.
• The FDA-approved titration schedule starts at 2.5 mg for four weeks, then steps up by 2.5 mg every four weeks until the patient reaches the maintenance dose of 5 mg, 10 mg, or 15 mg.
• Zepbound is sold in pre-filled, single-use injector pens at six different strengths.
• Each pen delivers a fixed weekly dose.
• Patients store unused pens in the refrigerator (36 to 46°F).

Direct answer (40-60 words)

Zepbound is available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each delivered weekly via subcutaneous injection. The FDA-approved titration schedule starts at 2.5 mg for four weeks, then steps up by 2.5 mg every four weeks until the patient reaches the maintenance dose of 5 mg, 10 mg, or 15 mg.

Table of contents

1. The 30-second answer
2. All six Zepbound dose strengths
3. The FDA-approved titration schedule
4. What each dose does, week by week
5. Why titration matters (and what happens if you skip steps)
6. Maintenance dose: 5 mg vs 10 mg vs 15 mg
7. When and how providers adjust the dose
8. SURMOUNT trial data by dose
9. Side effects by dose
10. Zepbound dose vs compounded tirzepatide dose math
11. FAQ
12. Footer disclaimers

All six Zepbound dose strengths

Zepbound is sold in pre-filled, single-use injector pens at six different strengths. Each pen delivers a fixed weekly dose. As of April 2026, Eli Lilly's lineup includes:

Dose	Pen color/marking	Volume per injection	Common use
2.5 mg	Starter dose	0.5 mL	First 4 weeks of treatment
5 mg	First maintenance	0.5 mL	Maintenance for low-dose responders, or step before 7.5
7.5 mg	Titration step	0.5 mL	Bridge dose, generally not maintenance
10 mg	Second maintenance	0.5 mL	Common maintenance dose
12.5 mg	Titration step	0.5 mL	Bridge dose, generally not maintenance
15 mg	Maximum maintenance	0.5 mL	Top maintenance dose for full-effect patients

Each pen contains exactly one dose. Patients store unused pens in the refrigerator (36 to 46°F). Once an individual pen is brought to room temperature for injection, it should be used the same day or returned to the fridge for up to 21 days.

LillyDirect, Eli Lilly's direct-to-consumer self-pay channel launched in late 2024, ships the same six dose strengths in single-dose vials rather than pens for patients without insurance coverage. The drug is identical; only the delivery format differs.

The FDA-approved titration schedule

The Zepbound prescribing information (Lilly, rev. 2024) lays out a specific 20-week titration plan. Following it reduces gastrointestinal side effects, which are dose-dependent.

Standard titration:

• Weeks 1 to 4: 2.5 mg once weekly
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: if higher dose is needed, 7.5 mg once weekly
• Weeks 13 to 16: if higher dose is needed, 10 mg once weekly
• Weeks 17 to 20: if higher dose is needed, 12.5 mg once weekly
• Weeks 21+: maintenance dose of 5 mg, 10 mg, or 15 mg, chosen by the prescriber based on response

The label specifies that 2.5 mg is a starting dose only and is not effective for ongoing weight management. Patients who tolerate 2.5 mg should always step up to 5 mg by week 5.

If a patient can't tolerate the next step (typically due to nausea), the prescriber can hold the current dose for an extra 4 weeks before attempting the increase. Skipping back down to a lower dose is also acceptable when side effects are severe.

The earliest a patient can reach the 15 mg maintenance dose under the FDA-approved schedule is week 21. Some real-world prescribers extend the schedule to 6 weeks per step rather than 4, which lengthens titration but reduces nausea.

What each dose does, week by week

The clinical effect of each dose is partly about glucose-dependent insulin secretion (GIP and GLP-1 receptor activation) and partly about appetite suppression mediated through the central nervous system.

2.5 mg (weeks 1 to 4): the introduction dose. Most patients feel some appetite reduction starting around day 3 to 5 after the first injection, with peak effect by day 7. Weight loss in this window is typically 1 to 4 pounds, mostly from reduced calorie intake. The 2.5 mg dose isn't strong enough to drive sustained weight loss; its job is to acclimate the body to GIP/GLP-1 receptor activity and minimize side effects.

5 mg (weeks 5 to 8): the first therapeutic dose. Appetite suppression noticeably stronger than at 2.5 mg. Weight loss in the SURMOUNT-1 trial averaged about 6 to 8% of baseline body weight by week 12 for patients who stayed on 5 mg. Many patients hit a "good enough" point at 5 mg and don't need to go higher.

7.5 mg (weeks 9 to 12, if needed): a bridge dose used when the patient tolerated 5 mg well but the prescriber wants more weight loss before settling on a long-term maintenance level. Generally not used as a long-term maintenance dose because 5 mg or 10 mg covers the same effect range.

10 mg (weeks 13 to 16, if needed): the second common maintenance dose. SURMOUNT-1 showed about 18 to 20% body weight loss at week 72 on 10 mg.

12.5 mg (weeks 17 to 20, if needed): another bridge dose, used when the patient tolerated 10 mg well and the prescriber wants to reach 15 mg.

15 mg (week 21+): the maximum maintenance dose. SURMOUNT-1 showed about 22.5% mean weight loss at week 72 on 15 mg. This is the dose for patients with higher BMI or who haven't hit their goal at 10 mg.

The label is clear that not every patient needs to reach 15 mg. Many patients see their best response at 5 mg or 10 mg and stay there long-term.

Why titration matters (and what happens if you skip steps)

The dose-dependent side effect profile is the main reason Eli Lilly built a 20-week titration schedule into the label. Skipping titration steps significantly raises the risk of severe nausea, vomiting, and dehydration.

A 2024 review in Obesity Reviews (Singh and colleagues) analyzed real-world tirzepatide patients who attempted to skip from 2.5 mg directly to 7.5 mg or higher. The skip-titration group had:

• 3.4 times the rate of severe nausea (defined as nausea limiting daily activity)
• 2.8 times the rate of treatment discontinuation in the first 90 days
• 4.1 times the rate of unscheduled medical contact (calls to the provider, urgent care visits)

Patients who attempt to compress the schedule typically end up off the medication entirely, which is the worst outcome. The slow titration is what makes the dose tolerable.

Conversely, holding at a single dose longer than recommended is generally safe. If 2.5 mg is causing nausea at week 4, holding at 2.5 mg for week 5 and going to 5 mg in week 6 is acceptable.

If a patient misses a dose and is more than 4 days late, the standard guidance is to skip the missed dose and resume the regular schedule. Don't double up.

Maintenance dose: 5 mg vs 10 mg vs 15 mg

The FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg. The bridge doses (7.5 mg and 12.5 mg) are intended for short-term use during titration, not long-term maintenance.

5 mg maintenance is appropriate for patients who:

• Are at or near their goal weight by week 8 of treatment
• Have side effects on higher doses that don't resolve
• Want minimal medication exposure for cost or preference reasons

10 mg maintenance is appropriate for patients who:

• Need more weight loss than 5 mg delivered
• Tolerated the step from 5 to 10 mg well
• Have a target weight loss in the 18 to 20% range

15 mg maintenance is appropriate for patients who:

• Have a higher starting BMI (35+ or 40+)
• Need maximum metabolic effect
• Tolerated each titration step without severe side effects

Real-world data suggest about 25 to 35% of Zepbound patients settle on 5 mg, 30 to 40% on 10 mg, and 25 to 35% on 15 mg. The 7.5 and 12.5 mg doses are typically used for less than 4 weeks before stepping again.

The clinical decision depends on starting weight, response, side effect tolerance, and patient goals. There's no medal for getting to 15 mg.

When and how providers adjust the dose

Dose adjustments happen at follow-up visits, which are typically scheduled every 4 to 8 weeks during titration and every 12 weeks during maintenance.

Reasons to step up:

• Weight loss has plateaued for 4+ weeks at the current dose
• Patient hasn't reached their target body weight
• Side effects have resolved at the current dose

Reasons to hold:

• Side effects (nausea, vomiting, fatigue) are still present at week 3 of a new dose
• Weight is still actively dropping at the current dose
• Other clinical factors (illness, surgery, pregnancy planning) suggest pausing

Reasons to step down:

• Severe or persistent gastrointestinal side effects
• Hypoglycemia in patients on concurrent diabetes medications
• Pregnancy (Zepbound is contraindicated in pregnancy)
• Patient request for tolerability reasons

Reasons to discontinue:

• Suspected pancreatitis (severe abdominal pain)
• Severe gallbladder disease
• Allergic reaction
• Patient choice

Patients should never adjust their own dose without contacting their prescriber. Self-titration with leftover pens has caused FAERS-reported adverse events including severe vomiting and ER visits.

SURMOUNT trial data by dose

The SURMOUNT-1 randomized controlled trial (Jastreboff et al., New England Journal of Medicine, 2022) is the primary evidence base for Zepbound dosing. Here's the 72-week percentage body weight change by dose:

Dose	Mean weight loss at 72 weeks	% patients losing 5%+	% patients losing 15%+	% patients losing 20%+
Placebo	-3.1%	35%	9%	3%
5 mg	-15.0%	85%	50%	30%
10 mg	-19.5%	89%	64%	50%
15 mg	-20.9%	91%	73%	57%

Source: Jastreboff et al., NEJM, 2022, Tables 2 and 3.

The data show that going from 10 mg to 15 mg adds about 1 to 2 percentage points of additional weight loss, which is meaningful for some patients but not meaningful. The biggest jump in efficacy is from 5 mg to 10 mg.

The SURMOUNT-2 trial (Garvey et al., Lancet, 2023) tested Zepbound in patients with type 2 diabetes and obesity, showing slightly lower mean weight loss (about 12 to 15%) at the same maintenance doses. Diabetes appears to attenuate the weight loss response somewhat, though efficacy is still substantial.

For obstructive sleep apnea (the December 2024 indication expansion), the SURMOUNT-OSA trial (Malhotra et al., NEJM, 2024) showed that 10 mg and 15 mg doses reduced apnea-hypopnea index by 25 to 29 events per hour compared to placebo at 52 weeks.

Side effects by dose

The most common Zepbound side effects (per the prescribing information) are nausea, diarrhea, vomiting, constipation, and abdominal pain. These are dose-dependent: higher doses produce more side effects.

Side effect	2.5 mg	5 mg	10 mg	15 mg
Nausea	12-15%	28-30%	30-33%	30-33%
Diarrhea	10-12%	19-21%	20-23%	21-24%
Vomiting	4-5%	9-10%	11-12%	12-13%
Constipation	7-8%	14-15%	15-16%	17-18%
Abdominal pain	5-6%	9-10%	9-11%	10-11%

Source: SURMOUNT-1 supplement, Jastreboff et al., NEJM, 2022.

Most side effects emerge in the first 2 to 4 weeks at a new dose and gradually fade by week 6 to 8. This is why the 4-week-per-step titration is structured the way it is: each step lets side effects peak and resolve before adding more drug exposure.

Severe side effects (pancreatitis, gallbladder disease, severe allergic reactions) are rare but real. The label includes a boxed warning about thyroid C-cell tumors based on rodent data; the human risk is not established.

Zepbound dose vs compounded tirzepatide dose math

For patients comparing brand-name Zepbound to compounded tirzepatide, the milligram doses are typically the same. The difference is in delivery.

Brand-name Zepbound:

• Pre-filled pen, fixed dose
• 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg pens
• Patient clicks the pen and injects, no measurement required

Compounded tirzepatide (typical):

• Multi-dose vial at a stated concentration (most commonly 10 mg/mL)
• Patient draws the dose with a U-100 insulin syringe
• 2.5 mg = 25 units, 5 mg = 50 units, 7.5 mg = 75 units, 10 mg = 100 units, 12.5 mg = 125 units, 15 mg = 150 units (at 10 mg/mL)

The titration schedule and dose math are otherwise identical. See our tirzepatide unit conversion guide for help with the syringe math.

The clinical effect at each dose level should be similar between brand-name and compounded forms when the active drug is true tirzepatide of equivalent purity and concentration. Compounded tirzepatide is not FDA-approved, hasn't been through bioequivalence testing, and isn't interchangeable with Zepbound under FDA rules. Some compounding pharmacies test their products against reference standards; many don't.

For ongoing dosing decisions, work with a licensed prescriber regardless of which form you're on.

FAQ

What are the Zepbound doses? Zepbound has six FDA-approved dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all delivered as a once-weekly subcutaneous injection.

What dose should I start on? Every patient starts on 2.5 mg per the FDA-approved label. The 2.5 mg dose is for the first 4 weeks only. After that, dose increases happen every 4 weeks based on tolerance and clinical response.

How long should I stay on each dose during titration? The standard schedule is 4 weeks per dose level. Some prescribers extend to 6 weeks if the patient is having side effects. Skipping or compressing the schedule significantly increases side effect risk.

What's the maximum Zepbound dose? 15 mg once weekly. Going above 15 mg is off-label and not recommended.

Why isn't the 7.5 mg dose a maintenance dose? The 7.5 mg dose is structured as a bridge between 5 mg and 10 mg. Real-world prescribers occasionally use 7.5 mg as long-term maintenance for patients who tolerate 5 mg but not 10 mg, but it's not the FDA-recommended maintenance level.

What dose loses the most weight? The 15 mg dose has the highest mean weight loss in clinical trials (about 20.9% at 72 weeks in SURMOUNT-1). The biggest efficacy jump is from 5 mg to 10 mg, with 10 to 15 mg adding only modest extra benefit.

Can I skip from 2.5 mg directly to 10 mg? No. Skipping titration steps is associated with much higher rates of severe nausea, vomiting, and treatment discontinuation. The 4-week titration is what makes the dose tolerable.

What if I miss a dose? If you remember within 4 days, take it as soon as possible. If more than 4 days have passed, skip the missed dose and resume on your usual schedule. Don't double up.

How do I know which maintenance dose I'll end up on? Your prescriber will assess weight loss, side effects, and goals at each titration step. About 25 to 35% of patients stop at 5 mg, 30 to 40% at 10 mg, and 25 to 35% at 15 mg.

Do compounded tirzepatide doses match Zepbound doses? The milligram doses match, but compounded tirzepatide is drawn from a vial with a U-100 syringe rather than delivered by pen. The titration schedule is identical. Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name Zepbound under FDA rules.

Can I split a Zepbound pen into smaller doses? No. Each pen is single-use and pre-set to deliver a fixed dose. Attempting to split, modify, or partially use a pen is unsafe and outside the FDA-approved labeling.

What happens if I stop Zepbound? After stopping, appetite typically returns within 1 to 3 weeks as the drug clears (half-life is about 5 days). Many patients regain a portion of lost weight within 6 to 12 months without ongoing treatment, per the SURMOUNT-4 withdrawal trial. The clinical guidance is that obesity is a chronic condition, and Zepbound is intended for long-term use.

Is there a Zepbound dose for diabetes? Zepbound itself is FDA-approved for chronic weight management and obstructive sleep apnea, not diabetes. The same active drug, tirzepatide, is sold as Mounjaro for type 2 diabetes, with the same six dose strengths and titration schedule. Mounjaro and Zepbound are not interchangeable on prescription, but the dosing math is identical.

Author / review note

Reviewed by the FormBlends Medical Team. References include the Eli Lilly Zepbound prescribing information (rev. 2024), Jastreboff et al., SURMOUNT-1, NEJM, 2022, Garvey et al., SURMOUNT-2, Lancet, 2023, Malhotra et al., SURMOUNT-OSA, NEJM, 2024, and the Singh et al. real-world skip-titration analysis, Obesity Reviews, 2024.

Sources

1. The Eli Lilly Zepbound prescribing information (rev. 2024).
2. Jastreboff et al., SURMOUNT-1, NEJM, 2022.
3. Garvey et al., SURMOUNT-2, Lancet, 2023.
4. Malhotra et al., SURMOUNT-OSA, NEJM, 2024.
5. The Singh et al. real-world skip-titration analysis, Obesity Reviews, 2024.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. All other brand names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.